LLY vs SYRE
Eli Lilly and Company vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
LLY
Eli Lilly and Company
68
Buy
VS
SYRE
Spyre Therapeutics, Inc.
72
Buy
| Metric | LLY | SYRE |
|---|
| AI Score |
68
|
72
|
| Price |
$1,180.33
|
$103.56
|
| P/E Ratio |
39.54×
|
-53.14×
|
| ROE |
77.8%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
84.0%
|
0.0%
|
| Debt / Equity |
1.62×
|
0.00×
|
| Dividend Yield |
0.6%
|
0.0%
|
| RSI (14) |
57.1
|
54.6
|
| Beta |
0.506
|
3.026
|
| Expected Upside |
+5.8%
|
—
|
AI Committee View
Current Innellis committee reasoning for LLY versus SYRE.
SYRE leads by 4 points.
SYRE scores 72/100 (Buy) versus LLY at 68/100 (Buy).
LLY Committee View
75% agreement
4 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
SYRE Committee View
100% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 79 -- overbought on the larger timeframe too — Technical